

Committee on the Environment, Public Health and Food Safety
The Chair

MK/VP/da
D(2023) 11597

D 303506 27.03.2023

Commissioner Stella KYRIAKIDES
European Commission
Health and Food Safety
200, rue de la Loi
BE - 1049 Brussels

Subject: Postponement of the pharmaceutical package legislation

Dear Commissioner,

Recently, we learned that the publication of the pharmaceutical package may be postponed yet again. As you know, it was originally scheduled for last year and then for 29 March 2023 and should include the revision of the pharmaceutical legislation, the revision of the EU legislation on medicines for children and rare diseases and the Council Recommendation on stepping up EU actions to combat antimicrobial resistance in a one health approach.

Parliament has consistently been calling for the presentation of legislative and non-legislative measures to implement the Pharmaceutical strategy to ensure the availability, affordability and security of supply of medicines and the strategic approach to pharmaceuticals in the environment to tackle pharmaceutical pollution. The legislation is particularly important to implement the lessons learned from the COVID-19 crisis.

As the Chair of the EP committee in charge of public health matters, I cannot stress enough the importance of these pieces of legislation. The ENVI coordinators have entrusted me to write this letter to you to underline the importance of starting the legislative work on the revision of the pharmaceutical legislation and the revision of the EU legislation on medicines for children and rare diseases as soon as possible, to enable Parliament to adopt its position in this term. If a short-term postponement cannot be avoided, we wish to stress that this postponement should be as time-limited as possible with a clear commitment to present the Commission proposals in April 2023 at the very latest.

We look forward to the exchange with you in the context of the structured dialogue in ENVI on 30 March which will be an occasion for ENVI Members to raise their questions and express their views *inter alia* on the future pharmaceutical package.

Yours sincerely,



Pascal CANFIN

